Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Vila Nova De Gaia – page 19

680 clinical trials in Vila Nova De Gaia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Vila Nova De Gaia at a glance
680
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

680 trials in Vila Nova De Gaia

Open in trial search

Malignant lymphoid neoplasm

Recruiting

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BMS-986515
  • Sponsor:Celgene Corp.

Plasma cell myeloma

Recruiting

Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Celgene Corp.

Migraine+2

Recruiting

Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, belumosudil and dexamethasone combination treatment for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Belumosudil Mesilate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, pomalidomide and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, evorpacept and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Acute lymphocytic leukaemia

Recruiting

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Karolinska University Hospital

Colitis ulcerative

Recruiting

Study on the Effects of Filgotinib for Children and Teenagers with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Colitis ulcerative+1

Recruiting

Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Vila Nova De Gaia

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancer, breast cancer, and multiple myeloma treatments. Studies include evaluations of novel therapies for both early-stage and metastatic conditions.

  • Advanced Head & Neck Squamous Cell Carcinoma
  • HER2-positive Breast Cancer
  • Multiple Myeloma Maintenance Therapy

Research encompasses targeted therapies and combination treatments aimed at improving patient outcomes.

02 Autoimmune Disorders

Comprehensive studies investigating treatments for various autoimmune conditions, including Sjögren's Syndrome and systemic sclerosis. Focus on developing targeted therapies for immune system regulation.

  • Primary Sjögren's Disease
  • Diffuse Cutaneous Systemic Sclerosis
  • Immune Thrombocytopenia

Evaluating novel biological therapies to address complex autoimmune manifestations.

03 Metabolic & Cardiovascular Studies

Research focused on obesity management and cardiovascular health. Studies evaluate new therapeutic approaches for weight management and cardiovascular disease prevention.

  • Obesity Treatment
  • Pulmonary Arterial Hypertension
  • Cardiovascular Risk Management

Investigating innovative treatments to address growing metabolic health challenges.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.